Roche Holding AG, the world’s biggest maker of cancer drugs, won U.S. approval to sell a gene mutation test that can help doctors pinpoint patients’ likelihood to respond to a popular treatment for lung cancer.
By the time Pfizer Inc., Johnson and Johnson, Elan Corp. and Eli Lilly & Co. announced their experimental medicines had shown limited benefit for Alzheimer’s patients in late-stage testing, the industry and academia had spent more than $30 billion researching amyloid plaque in the brain. Now they are working together to prevent such failures.
GlaxoSmithKline Plc and Theravance Inc.’s Breo Ellipta should be approved to treat a lung disorder that is the third-leading cause of death in the U.S., advisers to the Food and Drug Administration said.
Theravance Inc. surged the most in a year after a staff report by U.S. regulators showed the once- daily lung disease treatment the company is developing with GlaxoSmithKline Plc may be able to win approval.
Boehringer Ingelheim GmbH Chairman Andreas Barner may use product deals and regional acquisitions to fuel growth as the world’s largest family-owned drugmaker faces competition from lower-priced generics.